Literature DB >> 15528325

Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.

Philip A Stumbles1, Robyn Himbeck, Jeffrey A Frelinger, Edward J Collins, Richard A Lake, Bruce W S Robinson.   

Abstract

The cross-arming of effector CTL in response to cross-presented tumor Ags is predicted to fail in the absence of CD40 stimulation. However, questions remain regarding the role of CD40 signaling and additional CD4+ T cell-derived signals in this process. To address this, we have analyzed the cross-arming of tumor-specific CTL effectors in vivo in a mouse model of established tumor and tumor regression following CD40 activation. We found that tumor-specific CTL were constitutively cross-armed in tumor-draining lymph nodes during tumor growth and that systemic CD40 activation did not alter CTL cross-arming in the tumor-draining lymph nodes. Rather, CD40 activation induced peripheral dissemination of tumor-specific CTL effectors that required continual CD40 stimulation to maintain peripheral CTL and tumor regression. These data indicate that CD40 activation enhances the peripheral survival of constitutively cross-armed CTL and that persistent CD4+ T cell signals are required for their long-term activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528325     DOI: 10.4049/jimmunol.173.10.5923

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

2.  Enterotoxins can support CAR T cells against solid tumors.

Authors:  Bianca von Scheidt; Minyu Wang; Amanda J Oliver; Jack D Chan; Metta K Jana; Aesha I Ali; Fiona Clow; John D Fraser; Kylie M Quinn; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

3.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Authors:  Scott M J Cornwall; Matthew Wikstrom; Arthur W Musk; John Alvarez; Anna K Nowak; Delia J Nelson
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

Review 5.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

6.  Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Tae Heung Kang; Jin Hyup Lee; Chung Kil Song; Hee Dong Han; Byung Cheol Shin; Sara I Pai; Chien-Fu Hung; Cornelia Trimble; Jong-Seok Lim; Tae Woo Kim; T-C Wu
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

7.  Tumor antigen cross-presentation and the dendritic cell: where it all begins?

Authors:  Alison M McDonnell; Bruce W S Robinson; Andrew J Currie
Journal:  Clin Dev Immunol       Date:  2010-10-13

8.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

9.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.